Objective: Temsirolimus, an inhibitor of the mammalian target of rapamycin, is approved for treatment of patients with advanced renal cell carcinoma in the USA and Europe. Temsirolimus was not yet evaluated in East Asian patients. Methods: This non-randomized Phase II study enrolled 82 patients with advanced renal cell carcinoma [20 (24%) Japanese, 30 (37%) Korean and 32 (39%) Chinese patients; median age (range): 55 (26 -83) years]. Most (71%) received prior systemic therapy for metastatic disease; two-thirds were intermediate risk. Six Japanese patients received intravenous temsirolimus 20 mg/m 2 weekly for tolerability assessment (Group A); the remaining 76 received a 25 mg flat dose weekly (Group B). Temsirolimus was dosed once weekly. Primary efficacy end point was the Response Evaluation Criteria in Solid Tumors-defined clinical benefit rate in the intent-to-treat population. Results: In the entire population, regardless of treatment group, the clinical benefit rate was 48% (95% confidence interval: 36, 59). Objective response rate was 11% (95% confidence interval: 5, 20), median progression-free survival was 7.3 months (95% confidence interval: 4.0, 9.2) and median time to treatment failure was 5.4 months (95% confidence interval: 3.5, 7.4). No patient in Group A demonstrated dose-limiting toxicity. The most frequent Grade 3 or 4 drug-related adverse events were anemia, hyperglycemia, hypophosphatemia and stomatitis (5% each). Serious adverse events reported in 5% of patients were pneumonia (9%) and interstitial lung disease (7%). Temsirolimus and its major metabolite, sirolimus, were long-lived throughout the dosage interval, with no evidence of accumulation. Conclusion: Temsirolimus was well tolerated and showed promising activity in Japanese, Korean and Chinese patients with advanced renal cell carcinoma.
INTRODUCTION
Renal cell carcinoma (RCC), which constitutes 80 -85% of all kidney cancers, is a relatively common cancer in East Asian countries. A prevalence survey in Japan estimated 7405 persons newly diagnosed with RCC in 2002 and a crude annual incidence rate of 5.9 cases per 100 000 people (1) . Kidney cancer has been ranked as the 14th most common cause of cancer death in Japan (2009) (2) . In China, 29 000 cases of RCC were reported in 2007, with an incidence rate of 4.4 cases per 100 000 people, and the annual number of cases is expected to reach 57 000 by 2017 (3) . In Korea, the estimated incidence rate of all kidney cancers in 2007 was 5.8 per 100 000 people (4) . Up to 30% of patients with RCC present with metastatic disease, and another 40% of patients treated for localized RCC eventually relapse (5) .
Chemotherapy and hormonal therapy are ineffective in advanced RCC. Cytokine-based immunotherapy with interferon (IFN) alpha or interleukin-2 is associated with a high rate of adverse events (AEs) and provides only modest response rates (10 -20%), with few patients achieving longterm disease-free survival (6) . In addition to stage classification, risk factors that negatively affect prognosis include five factors defined by the Memorial Sloan-Kettering Cancer Center (MSKCC) group (7, 8) : increased lactate dehydrogenase level, hypercalcemia, anemia, an interval of ,1 year from diagnosis to treatment and poor Karnofsky performance status. A sixth poor-risk factor is the presence of multiple organ sites of metastasis (9) .
Since 2004, the treatment paradigm for RCC has changed dramatically, with the introduction of molecularly targeted therapies that have demonstrated superior efficacy compared with IFN therapy in large, randomized, controlled clinical trials (10) . Unfortunately, clinical data are lacking for these targeted agents in patients of East Asian ethnicity.
Temsirolimus is a selective inhibitor of the mammalian target of rapamycin (mTOR) kinase, which plays a key role in cell growth and proliferation signaling pathways by regulating protein synthesis (11) . Single-agent temsirolimus demonstrated promising activity in cytokine refractory patients with advanced RCC in a Phase II study, particularly in patients who had poor-risk factors (12) . Subsequently, in the Phase III global advanced renal cell carcinoma (ARCC) trial, temsirolimus 25 mg administered intravenously (IV) once weekly demonstrated improved overall survival (OS) compared with IFN (10.9 months vs. 7.3 months; log rank P ¼ 0.0078) and longer progression-free survival (PFS) in previously untreated patients with advanced RCC who were poor risk based on the presence of three of six adverse prognostic factors (13) . Temsirolimus had an acceptable safety profile; the most frequent Grade 3 or 4 AEs were anemia (20%), asthenia (11%), hyperglycemia (11%) and dyspnea (9%). Based on these findings, temsirolimus was approved in the USA for the treatment of patients with advanced RCC, and in Europe for first-line treatment of patients with advanced RCC who have at least three of the six prognostic risk factors. Japan, China and Korea did not participate in the Phase III global ARCC trial.
Here, we report interim results from a Phase II study investigating the safety and efficacy of temsirolimus 25 mg IV once weekly in Japanese, Chinese and Korean patients with advanced RCC. A previous Phase 1 study of temsirolimus in 10 Japanese patients with advanced solid tumors established the maximum tolerated dose at 15 mg/m 2 , owing to doselimiting toxicities (DLTs) observed at the next-higher dose level (45 mg/m 2 ) (14) . To address concerns pertaining to administration of the 25 mg flat dose to lower-weight Japanese patients, the tolerability and pharmacokinetics (PK) of temsirolimus 20 mg/m 2 were assessed in a small cohort of Japanese patients.
PATIENTS AND METHODS

PATIENT POPULATION
The study population comprised patients of Japanese, Korean or Chinese ethnicity aged 20 years (Group A only: 20 and ,75 years) with histologically confirmed advanced (Stage IV or current disease) RCC and 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) (15) . Other inclusion criteria included Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1; fasting serum cholesterol level 350 mg/dl and triglyceride level 400 mg/dl; adequate renal, hepatic, cardiac and pulmonary function and life expectancy of 3 months. Patients with the following parameters were excluded: history of or known brain metastases; prior RCC treatment, surgery or tumor embolization within 4 weeks of the start of study treatment; unresolved acute toxic effects of prior RCC therapy to Grade 1, classified according to the National Cancer Institute's Common Terminology Criteria for AEs (CTCAE) version 3.0; any secondary malignancy within the previous 5 years; prior treatment with an mTOR inhibitor; active acute or chronic infection or serious intercurrent illness; cardiovascular disease and the use of ongoing maintenance therapy for life-threatening arrhythmia, pulmonary hypertension or pneumonitis. All patients gave written informed consent. This study was approved by the institutional review board at each participating center and was conducted in accordance with the International Conference on Harmonization Guideline for Good Clinical Practice.
STUDY DESIGN
This was a Phase II, non-randomized, open-label, multicenter, outpatient study of temsirolimus. Temsirolimus was administered IV once weekly. In Japan, a subset of six patients (Group A) received temsirolimus 20 mg/m 2 for tolerability assessment at this dose level. These patients were hospitalized for the first four doses and had frequent physical and laboratory evaluations. A larger outpatient cohort Jpn J Clin Oncol 2012;42 (9) 837 consisting of patients in Japan, Korea and China (Group B) received temsirolimus at a flat dose of 25 mg. Dose adjustments were allowed according to protocolspecified guidelines. Random allocation was not applied for the enrollment of Japanese patients for Group A and Group B. Patients in Group A and patients in Group B were enrolled simultaneously. For both groups, temsirolimus treatment was continued until disease progression, unacceptable toxicities or withdrawal of consent.
STUDY ASSESSMENTS
Patients were screened within 28 days prior to treatment initiation. Baseline evaluations included physical examination; ECOG PS; hematology; biochemistry; tumor assessments [scanned by computed tomography (CT) or magnetic resonance imaging]; 12-lead electrocardiography (ECG); echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scans; pulmonary function tests (PFTs) and oxygen saturation by pulse oximetry.
The primary efficacy end point was investigator assessed clinical benefit rate (CBR), defined as the proportion of patients with a complete response (CR) or partial response (PR) or stable disease (SD) 24 weeks according to RECIST (15) . Tumor assessments were scheduled every 8 weeks until disease progression. Secondary end points included PFS, objective response rate (ORR; CR þ PR), duration of response, time to treatment failure (TTF) and OS. Subgroup analyses for key efficacy end points were also performed for exploratory purposes.
Safety and tolerability were evaluated at regular intervals using the following assessments: monitoring of AEs, serious AEs and withdrawals or treatment modification due to AEs; physical examinations; laboratory assessments; ECG; ECHO or MUGA scan; PFTs; oxygen saturation; CT scans and concomitant medications for management of AEs. Severity of AEs was graded using CTCAE version 3.0.
Whole-blood samples for PK assessments were collected from all patients. Temsirolimus and sirolimus, the major active metabolite, were measured by validated liquid chromatography/tandem mass spectrometry assays (16, 17) . For Group A, samples were collected at the following time points: 0 ( pre-dose), 0.5 (end of infusion), 1, 2, 6, 24, 72 and 96 h during Weeks 1 and 4 of treatment, and 0 h on Weeks 2, 3 and 5. In all remaining patients (Group B), samples were collected at 0 h during Weeks 1 -5, and during Week 4 at 2 and 72 h.
Non-compartmental analysis was performed using WinNonlin AutoPilot to derive temsirolimus and sirolimus PK parameters. Population PK analysis using NONMEM VI was applied for combined data from Group A and Group B. Separate population PK models were constructed to describe temsirolimus and sirolimus disposition. For temsirolimus, the PK profile was fitted to a three-compartment model with factors for non-linear dose effect, multiple dose decrease in exposure and intersubject variability. For sirolimus, a standard two-compartmental model with firstorder absorption and intersubject variability was applied. Associations of exposure to relevant AEs were examined by graphically comparing observed individual PK parameters estimated by Bayesian method with population parameters.
STATISTICAL METHODS
Efficacy analyses were conducted for the intent-to-treat (ITT) population, defined as all patients who enrolled in the study; the safety population consisted of all patients who received 1 dose of temsirolimus. The PK population was defined as all patients who received 1 dose of temsirolimus and for whom 3 measurable blood concentration samples were available.
The primary analysis was conducted 32 weeks after the last patient received his or her first dose of temsirolimus. No formal statistical testing was planned for this study. Evaluation of the data consisted primarily of summary displays (i.e. descriptive statistics and tabulations). The CBR and ORR were binomial, and their 95% confidence intervals (CIs) were calculated using the Clopper -Pearson method. The distributions and median times of PFS, OS and TTF were estimated by the Kaplan -Meier method, and 95% CIs for median times were constructed using the BrookmeyerCrowley method (18) .
The study was planned to include 80 patients (20 Japanese, 30 Chinese and 30 Korean). The null hypothesis (uninteresting CBR) was set at 20% and the alternative hypothesis (sufficiently promising CBR) was set at 40%. With a sample size of 80 patients, there was an 97% chance that the 95% CI for the CBR excluded 20% when the true rate was 40%. The number of patients in each country was based on clinical considerations. CLINICAL TRIAL NUMBER NCT00494091.
RESULTS
PATIENTS
A total of 82 patients were enrolled and received temsirolimus: 6 patients in Group A in Japan (20 mg/m 2 ) and 76 in Group B (25 mg). Clinical characteristics at baseline are shown in Table 1 . All six Japanese patients in Group A were males and the median age was 58 years (range: 49 -74). Of the patients in Group B, 14 were enrolled in Japan, 30 in Korea and 32 in China. All 82 enrolled patients were included in both the ITT and safety populations.
Clear cell carcinoma (82%) was the predominant tumor histology. Approximately 85% of patients had at least two metastatic organ sites, most frequently the lungs (81%) and lymph nodes (59%). All patients had an ECOG PS of 0 -1. Most patients (94%) previously underwent nephrectomy and/
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Temsirolimus in East Asian patients with RCC or received prior systemic therapy for metastatic disease (71%); 46% of patients had received 2 prior therapies. At baseline, two-thirds of the patients were in the intermediate MSKCC risk group.
TREATMENT AND DISPOSITION
The primary analysis for this report was conducted 32 weeks after the last patient had his or her first dose of temsirolimus. The database cutoff was June 2009. At that time, 41 patients had withdrawn from the study and 35 had died. Reasons for withdrawal included disease progression, n ¼ 25; AEs, n ¼ 7; unknown reason, n ¼ 3; lost to followup, n ¼ 2 and four requests). Two AEs, interstitial lung disease (ILD) and pneumonia, were considered drug related. A total of 13 patients remained on treatment (2 in Group A and 11 in Group B) and 28 were in follow-up. A final analysis is planned after the final database of this study becomes available.
The median duration of temsirolimus treatment was 21.5 weeks, and 19 patients (23%) remained on treatment for at least 48 weeks. Most patients were able to receive close to the planned dose of temsirolimus. The median dose intensity was 18.85 mg/m 2 /week in Group A and 23.79 mg/week in Group B, which translated to median relative dose intensities of 0.94 and 0.95, respectively. Relative dose intensity in Group B was 0.77 for Japanese patients, 1.00 for Korean patients and 0.94 for Chinese patients.
EFFICACY
Clinical benefit was observed for 39 of 82 patients ( Table 2) . The CBR as reported by investigators was 47.6% (95% CI: 36.4, 58.9), which demonstrated that the 95% CI excluded Jpn J Clin Oncol 2012;42(9) 839 an uninteresting rate of 20%. No patient had a CR and 9 (11%) patients had a PR, resulting in an ORR of 11.0% (95% CI: 5.1, 19.8). Median duration of objective response was not reached at this time because of insufficient patient follow-up. An additional 37% of patients had SD for 24 weeks. The maximum reduction from baseline in target tumors for all 82 patients is shown in Fig. 1 .
Median TTF was 5.4 months (95% CI: 3.5, 7.4). The median PFS was 7.3 months (95% CI: 4.0, 9.2) ( Table 2 ; Fig. 2A ). The median OS was 19.8 months (95% CI: 12.5; not reached) ( Table 2 ; Fig. 2B ). However, the OS estimates were immature at this time due to insufficient patient followup; only 35 (43%) patients had death dates and 47 (57%) patients were censored. Analysis of efficacy by ethnic group resulted in the following CBRs: Japanese, 71.4% (10/14); Korean, 40.0% (12/ 30); Chinese 43.8% (14/32). Median PFS for Japanese, Korean and Chinese patients were 10.0, 3.8 and 7.7 months, respectively. Possible apparent variation in efficacy among the ethnic groups might be ascribed to differences in patient characteristics (i.e. performance status and MSKCC risk group distributions) and/or differences in the medical practices between these three countries.
SAFETY
The six Japanese patients in Group A were monitored carefully for DLTs during the tolerability evaluation period, from the first temsirolimus infusion to immediately before the fourth dose. No patient in Group A had an AE that met the criteria for a DLT.
Overall, 81 (99%) patients experienced treatment-related AEs, the majority of which were Grade 1 or 2 in severity ( Table 3 ). The most commonly reported treatment-related AEs were rash (59%), stomatitis (57%), hypercholesterolemia (43%), hypertriglyceridemia (39%) and anorexia (37%). Approximately two-thirds of patients experienced 1 Grade 3 or 4 treatment-related AE; those observed in more than two patients were anemia, stomatitis, pneumonia, hyperglycemia and hypophosphatemia [four patients (5%) each] and hypercholesterolemia, hypertriglyceridemia and ILD [three patients (4%) each]. Serious AEs occurring in .5% of patients were pneumonia (any causality, 9%; drug-related, 5%) and ILD (any causality and drug-related, 7% each). One patient experienced a treatment-related Grade 5 AE ( pneumonia). Treatment-related AEs (all grades and Grade 3 or 4) were similar between the Japanese, Korean and Chinese populations.
AEs leading to treatment discontinuation occurred in 23 patients (28%), dose delay in 49 (60%) and dose reduction in 26 (32%). ILD was the only treatment-related AE leading to discontinuation in more than two patients (n ¼ 7) and was the most frequent cause for dose delay or dose reduction (n ¼ 5 and n ¼ 10, respectively).
PHARMACOKINETICS
All six Japanese patients in Group A received 20 mg/m 2 temsirolimus by a 30 min IV infusion. One patient during Week 1 and one patient during Week 4 had aberrant measurements and, owing to the small sample number, were excluded from the analysis of non-compartmental PK parameters (Table 4 ). The maximum temsirolimus concentration (C max ) was observed at the end of infusion, and the mean elimination half-life of temsirolimus was 18.6 h. For sirolimus, the mean terminal half-life was 54.7 h. The C max and AUC for temsirolimus and sirolimus were not changed Increased creatinine level between Week 1 and Week 4 data, indicating no accumulation after multiple doses. Population PK modeling included discrete concentration measurements from 80 patients (240 observations for temsirolimus and 532 observations for sirolimus). Figure 3 shows the results of visual predictive checks of the final temsirolimus and sirolimus population PK models for patients receiving 25 mg IV temsirolimus. Of the covariates tested [dose, body weight, body surface area, sex, number of doses (after first dose or after second dose), country], none had a statistically significant effect on temsirolimus or sirolimus disposition.
DISCUSSION
This Phase II trial is the first study evaluating temsirolimus in East Asian patients with advanced RCC. Interim results demonstrate that temsirolimus 25 mg IV once weekly was effective and well tolerated in Japanese, Korean and Chinese patients with advanced RCC. A dose of 20 mg/m 2 was well tolerated in a subgroup of six Japanese patients.
In the primary analysis, clinical benefit (OR or SD for 24 weeks) was observed in 48% (95% CI: 36, 58) of patients. The lower 95% confidence limit exceeded the prespecified threshold value (20%) for a finding of interest. Secondary end points included ORR (11%); median PFS (7.3 months), and median TTF (5.4 months). Consistent with efficacy findings from other clinical trials of temsirolimus in advanced RCC (12, 13) , long-term SD (rather than OR) was the major component of clinical benefit.
The 25 mg once-weekly dose of temsirolimus, which was evaluated in this study, is the approved recommended dose in the USA and Europe for treatment of patients with advanced RCC. The types and frequencies of treatment-related AEs were consistent with those reported in other patients receiving temsirolimus (12, 13) . Rash and stomatitis were the most common event, and the most frequent Grade 3 or higher events were anemia, stomatitis, pneumonia, hyperglycemia and hypophosphatemia.
After once-weekly IV administration of temsirolimus 20 mg/m 2 or 25 mg (flat dose), temsirolimus and its active metabolite, sirolimus, were long-lived throughout the dosing interval. There was no statistically significant covariate for explaining variability in temsirolimus or sirolimus clearance. The PK parameters were similar to those previously observed in patients with advanced RCC treated with the 25 mg dose (12) . Population PK modeling also yielded comparable parameters as were obtained for final models for pooled population PK analyses in patients with cancer (19) . Taken together, these findings suggest that no dose adjustment is required based on East Asian ethnicity.
ILD or pneumonitis is a class effect associated with rapamycin and its analogs. In the global ARCC Phase III trial, treatment-related pneumonitis was reported in 2% of patients receiving temsirolimus (13) . A retrospective analysis of the global ARCC trial showed that 29% (52 of 178 evaluable patients) developed radiographically identified drug-related pneumonitis (20) . In our study, treatment-related ILD was reported in 17% (14 patients) and was the most frequent cause of treatment discontinuation or dose modification. There was no apparent correlation between the occurrence of ILD and temsirolimus or sirolimus exposure. An independent advisory board was convened to further evaluate cases of ILD radiographically; these findings will be reported separately. Briefly, 38 patients developed radiographic evidence of ILD, and approximately half of these patients also reported accompanying respiratory AEs. Onset or worsening of preexisting evidence of ILD occurred within the first 4 months of treatment in the majority of patients. Nevertheless, patients who received temsirolimus beyond 4 months continue to be monitored closely for development of ILD, and their management is altered if clinical symptoms appear.
The current study population was substantially different from that of the global ARCC trial. Whereas the global 
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Temsirolimus in East Asian patients with RCC ARCC trial enrolled only previously untreated patients, most (72%) of the patients in Group B of this study received prior systemic therapy in the metastatic setting, including tyrosine kinase inhibitor (TKI) therapy in 31 (41%) patients. The CBR for patients who received a prior TKI (42%, 13/31) was not much different from that observed for patients who received no prior therapy (43%, 9/21) or other prior therapies (58%, 14/24). This study population also differed from that of the global ARCC trial with respect to prognostic risk. Whereas the population was predominantly MSKCC intermediate risk (66% of patients), the global ARCC trial was mainly MSKCC poor risk (74% patients). Also, 3 of 6 modified risk factors were present at baseline for only 44% of patients compared with 94% of patients in the global ARCC trial. Despite several differences in patient backgrounds between the two studies, including ethnicity and previous therapy, the median PFS intervals appear to be similar for those patients with 3 of 6 modified risk factors [i.e. 3.6 months in the subset analysis of the present study compared with 3.8 months (95% CI: 3.6, 5.2; investigator assessed) for patients in the temsirolimus-alone arm of the global ARCC trial] (13). Given the paucity of available clinical data for temsirolimus treatment in East Asian patients with advanced RCC, these interim results provide important, urgently needed information on efficacy and safety. The findings suggest that temsirolimus may be a treatment option for patients with advanced RCC in Japan, Korea and China. With longer follow-up, the data continue to mature; a subsequent report of final results is planned.
CONCLUSIONS
Temsirolimus 25 mg IV administered once weekly displayed promising efficacy and an acceptable safety profile in Japanese, Korean and Chinese patients with advanced RCC. Alternative dosing with 20 mg/m 2 weekly in Japanese patients was also well tolerated. Safety, efficacy and PK profiles in this East Asian population were consistent with those observed for other ethnicities.
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